MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
TherapeuticsMD Revenue 2011-2026 | TXMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue TherapeuticsMD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.02 M | 1.76 M | 1.3 M | 70 M | 2.57 M | 64.9 M | 49.6 M | 16.1 M | 16.8 M | 19.4 M | 20.1 M | 15 M | 8.78 M | 3.82 M | 2.09 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70 M | 1.3 M | 19.7 M |
Quarterly Revenue TherapeuticsMD
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 724 K | 784 K | 952 K | 393 K | - | 547 K | 234 K | 313 K | - | -53 K | 437 K | 416 K | - | 354 K | 348 K | 695 K | 18.7 M | 25.4 M | 23 M | 19.9 M | 22.6 M | 19.3 M | 10.7 M | 12.3 M | 15.9 M | 23.7 M | 6.08 M | 3.95 M | 5.09 M | 3.47 M | 3.76 M | 3.77 M | 4.12 M | 4.42 M | 4.25 M | 3.99 M | 4.49 M | 5.54 M | 4.4 M | 4.93 M | 5.63 M | 5.19 M | 4.85 M | 4.48 M | 4.26 M | 4.19 M | 3.75 M | 2.83 M | 2.86 K | 2.29 M | 2.08 M | 1.54 M | 1.24 K | 1.04 M | 819 K | 722 K | - | 540 K | 508 K | 486 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.4 M | -53 K | 5.45 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 5.87 | 6.53 % | $ 87.2 M |  USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 2.74 | 0.37 % | $ 1.05 B | Canada |
 |
Harrow Health
HROW
|
272 M | $ 33.0 | 0.12 % | $ 1.21 B | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 2.66 | - | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 23.35 | -0.55 % | $ 1.08 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 5.47 | 0.37 % | $ 2 B | Canada |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Tilray
TLRY
|
627 M | $ 5.29 | -3.11 % | $ 3.27 B | Canada |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 6.62 | 1.85 % | $ 579 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.46 | -2.81 % | $ 190 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 1.1 | 3.77 % | $ 1.37 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.12 | -0.88 % | $ 107 M | Canada |
 |
Evolus
EOLS
|
297 M | $ 6.09 | -5.58 % | $ 393 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.45 | -1.36 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
743 M | $ 8.45 | 0.96 % | $ 433 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.35 | 5.86 % | $ 34.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
19.2 M | $ 0.76 | -2.32 % | $ 3.06 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 23.44 | 0.3 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 7.04 | -2.36 % | $ 278 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 0.73 | 3.0 % | $ 36.5 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
14.3 B | $ 16.65 | 1.15 % | $ 19.4 B | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 0.79 | -2.06 % | $ 28.4 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.76 | -0.29 % | $ 3.26 M |  China |